Maria Holyanova

The debate now is the importance of psychological support in trials investigating psychedelic-assisted therapy.

While everyone was preparing to head to Wonderland Miami, the psychedelic space saw a week full of debates! From the FDA's recommendation to limit psy

Psilocybin can be an useful tool when it comes to reducing nicotine withdrawal, PTSD, and even OCD symptoms. It could also be a hazardous weapon for t

Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach t

In the event you begin experiencing signs of tetany during a trip and a simple bottle of water isn't sufficient to reduce symptoms, you should conside

While yet another study shows psilocybin's efficacy in treating depression in cancer patients, and 2024 presidential candidates push for a psychedelics reform from all sides, Colorado public health officials fight over manure.

As MDMA nears FDA approval, LSD's efficacy in treating generalized anxiety disorder is demonstrated in MindMed's Phase 2b study. Meanwhile, Congress has approved a psychedelic treatment bill for active duty service members suffering from PTSD.

If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which drive new investment into research in mental health.

The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.